<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35521048</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2050-0904</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical case reports</Title>
          <ISOAbbreviation>Clin Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Case report: Bilateral simple Syndactyly in a toddler with maternal exposure to cabergoline.</ArticleTitle>
        <Pagination>
          <StartPage>e05795</StartPage>
          <MedlinePgn>e05795</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e05795</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/ccr3.5795</ELocationID>
        <Abstract>
          <AbstractText>Cabergoline is routinely prescribed in the management of prolactin excreting adenomas and is associated with low risk of congenital malformations and teratogenicity. Here, we reported the case of a bilateral simple syndactyly in a toddler with maternal exposure to cabergoline during the pregnancy. This association has not been previously described before.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Clinical Case Reports published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Afshar</LastName>
            <ForeName>Shima</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy School of Pharmacy Shahid Beheshti University of Medical Sciences Tehran Iran.</Affiliation>
              <Identifier Source="RINGGOLD">556492</Identifier>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abbasinazari</LastName>
            <ForeName>Mohammad</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy School of Pharmacy Shahid Beheshti University of Medical Sciences Tehran Iran.</Affiliation>
              <Identifier Source="RINGGOLD">556492</Identifier>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Darvishi</LastName>
            <ForeName>Behnam</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics Rasoul Akram Hospital Iran University of Medical Sciences Tehran Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ziaie</LastName>
            <ForeName>Shadi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy School of Pharmacy Shahid Beheshti University of Medical Sciences Tehran Iran.</Affiliation>
              <Identifier Source="RINGGOLD">556492</Identifier>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Esmaily</LastName>
            <ForeName>Hadi</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0001-6915-6028</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy School of Pharmacy Shahid Beheshti University of Medical Sciences Tehran Iran.</Affiliation>
              <Identifier Source="RINGGOLD">556492</Identifier>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Case Rep</MedlineTA>
        <NlmUniqueID>101620385</NlmUniqueID>
        <ISSNLinking>2050-0904</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Syndactyly</Keyword>
        <Keyword MajorTopicYN="N">cabergoline</Keyword>
        <Keyword MajorTopicYN="N">malformation</Keyword>
        <Keyword MajorTopicYN="N">pregnancy</Keyword>
      </KeywordList>
      <CoiStatement>The authors hereby declare that there exists no known competing interests or individual relationships, which may have influenced the findings presented in this manuscript.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35521048</ArticleId>
        <ArticleId IdType="pmc">PMC9066742</ArticleId>
        <ArticleId IdType="doi">10.1002/ccr3.5795</ArticleId>
        <ArticleId IdType="pii">CCR35795</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Melmed S, Braunstein GD, Chang JR, Becker DP. Pituitary tumors secreting growth hormone and prolactin. Ann Intern Med. 1986;105(2):238‐253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3524338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kredentser JV, Hoskins CF, Scott JZ. Hyperprolactinemia—a significant factor in female infertility. Am J Obstet Gynecol. 1981;139(3):264‐267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7468693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Greer ME, Moraczewski T, Rakoff JS. Prevalence of hyperprolactinemia in anovulatory women. Obstet Gynecol. 1980;56(1):65‐69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7189848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mah PM, Webster J, editors. Hyperprolactinemia: etiology, diagnosis, and management. Seminars in reproductive medicine; 2002: Copyright© 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New.</Citation>
        </Reference>
        <Reference>
          <Citation>
Molitch ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am. 1999;28(1):143‐169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10207689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA. 1982;247(11):1589‐1591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7062462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med. 1999;44(12 suppl):1121‐1126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10649822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27(5):485‐534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16705142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ferrari C, Mattei A, Melis GB, et al. Cabergoline: long‐acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab. 1989;68(6):1201‐1206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2656736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ciccarelli E, Giusti M, Miola C, et al. Effectiveness and tolerability of long term treatment with cabergoline, a new long‐lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab. 1989;69(4):725‐728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2570790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL. Pregnancy outcomes following cabergoline treatment: extended results from a 12‐year observational study. Clin Endocrinol. 2008;68(1):66‐71.</Citation>
        </Reference>
        <Reference>
          <Citation>
Ricci E, Parazzini F, Motta T, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol. 2002;16(6):791‐793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12401507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol. 1996;10(4):333‐337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8829257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ono M, Miki N, Amano K, et al. Individualized high‐dose cabergoline therapy for hyperprolactinemic infertility in women with micro‐and macroprolactinomas. J Clin Endocrinol Metab. 2010;95(6):2672‐2679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20357175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gillam MP, Fideleff H, Boquete HR, Molitch ME. Prolactin excess: treatment and toxicity. Pediatr Endocrinol Rev. 2004;2:108‐114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16456489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stalldecker G, Mallea‐Gil MS, Guitelman M, et al. Effects of cabergoline on pregnancy and embryo‐fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary. 2010;13(4):345‐350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20676778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Malik S. Syndactyly: phenotypes, genetics and current classification. Eur J Hum Genet. 2012;20(8):817‐824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3400728</ArticleId>
            <ArticleId IdType="pubmed">22333904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Temtamy SA.The genetics of hand malformations: updated. Congenit Anom. 1985;25:73‐92. doi:10.1111/j.1741-4520.1985.tb00636.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1741-4520.1985.tb00636.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lebbe M, Hubinont C, Bernard P, Maiter D. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol. 2010;73(2):236‐242.</Citation>
        </Reference>
        <Reference>
          <Citation>
Ahmed H, Akbari H, Emami A, Akbari MR. Genetic overview of syndactyly and polydactyly. Plast Reconstruct Surg Global Open. 2017;5(11):e1549.</Citation>
        </Reference>
        <Reference>
          <Citation>
Garbis H, Elefant E, Diav‐Citrin O, et al. Pregnancy outcome after exposure to ranitidine and other H2‐blockers: a collaborative study of the European Network of Teratology Information Services. Reprod Toxicol. 2005;19(4):453‐458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15749258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Danielsson B, Wikner BN, Källén B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol. 2014;50:134‐137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25450422</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
